Tuberculosis cost in tunisia

##plugins.themes.academic_pro.article.sidebar##

Published May 18, 2017
Download
Vol. 94 No. 10 (2016): Issue Oct 2016

##plugins.themes.academic_pro.article.main##

Mohamed Hsairi
Mehdi Ben Braham
Dhikrayet Gamara
Rachid Fourati
Faouzi Abid
Fatma Tritar
Mohamed Ridha Charfi

Abstract

Background: Tuberculosis (TB) infects one third of the world population. Its economic impact is important, affecting the global economy in the World.
 Objective: To determine the economic costs related to tuberculosis in Tunisia.
Methods:Calculations were made for the citationsRaw year 2013; we covered all cost components of the disease, which are related to program management, BCG vaccination, health workers training, social mobilization, screening, chemoprophylaxis, and tuberculosis care. With the exception of costs related to care, which were the subject of a specific survey, the costs of other categories were obtained from the National TB Control Program.
Results: The cost of the different components related to the management, prevention, screening and tuberculosis care in 2013 amounted 504688,000DT. The cost of care represented 80.0% of total costs (6807 808,000DT) ; cost related to program  management represented 13.2% (1 121 580,00 DT) and the BCG vaccination  6.0% e (512 300,00DT) The average cost per patient was 1447,360 DTin 2013.
Conclusion
Reducing the cost of tuberculosis, would involve reducing diagnostic delay. It is also recommended to reduce hospitalization recourse, and prevent multidrug resistance which lead to additional expenditures.

Keywords:

tuberculosis, cost, tunisia

##plugins.themes.academic_pro.article.details##

References

  1. FitzGerald JM, Houston S. Tuberculosis 8.The disease in associationwith HIV infection.Canadian Medical Association Journal,1999, 161(1): 47-51.
  2. WHO Global TB Programme.Anti-tuberculosis drug resistance in the world. Geneva, World Health Organization,1997.
  3. Global tuberculosis control: surveillance, planning and financing.Geneva, World HealthOrganization, 2006.
  4. Global tuberculosis control: surveillance, planning, financing.Geneva, World Health Organization, 2008 (WHO/HTM/TB/2008.393).
  5. World HealthOrganization.(2012). Global Tuberculosis Report 2014.Switzerland
  6. TB Alliance.Economic Impact of TB. 2013. http://www.tballiance.org/why/economic-impact.php
  7. Holmes, C., Hausler, A., & Nunn, P. (1998).A review of sex differences in the epidemiology of tuberculosis.International Journal of Tuberculosis and Lung Disease, 2, 96-104.
  8. Hudelson, P. (1996). Gender differentials in tuberculosis: The role of socioeconomic and cultural factors.Tubercle and Lung Disease, 77, 391-400.
  9. Murray, C. (1991).Social, economic and operational research on tuberculosis: recent studies and some priority questions.Bulletin of the International Union on Tuberculosis and Lung Disease, 66, 149-156.Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1687507.
  10. Kim, J. Y., Shakow, A., Castro, A., Vande, C., & Farmer, P. (2003).Tuberculosis Control.In Richard Smith, R. Beaglehole, D. Woodward, & N. Drager (Eds.), Global Public Goods for Health (GPGH). Oxford: Oxford University Press. Retrieved from http://www.who.int/trade/distance_learning/gpgh/gpgh3/en/index7.html
  11. The economic impacts of tuberculosis.Geneva, World HealthOrganization, 2000.
  12. Ministère De La Sante Publique/ Direction de la Pharmacie et du Médicament. FORMULAIRE THERAPEUTIQUE TUNISIEN. Deuxièmeédition. http://www.dpm.tn
  13. Ministère De La Sante Publique. Nomenclature des actes des professions de santé.
  14. Tadayuki Tanimura, Ernesto Jaramillo, Diana Weil, Mario Raviglione and Knut Lo¨nnroth Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. Eu0 Respir J 2014; 43: 1763-1775
  15. Mancuso JD, Niebuhr DW, Frick KD, et al. Cost-Effectiveness analysis of targeted and sequential screening strategies for latent tuberculosis.Int J Tuberc Lung Dis 2011; 15: 1223-1330.
  16. Holland DP, Sanders GD, Hamilton CD, et al. Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. PLoS One 2011; 6: e22276.
  17. Kowada A, Deshpande GA, Takahashi O, et al. Cost effectiveness of interferon-gamma release assay versus chest X-ray for tuberculosis screening of BCG-vaccinated elderly populations. MolDiagnTher2010; 14: 229-236.
  18. Kik S, Olthof S, de Vries J, Menzies D, Kincler N, van Loenhout-Rooyakkers J, et al. Direct and indirect costs of tuberculosis among immigrant patients in the Netherlands. BMC Public Health.2009; 9(1): 283.
  19. Ray TK, Sharma N, Singh MM, Ingle GK. Economic burden of tuberculosis in patients attending DOT centres in Delhi. J Commun Dis. 2005; 37(2): 93-98.
  20. Kik S, Olthof S, de Vries J, Menzies D, Kincler N, van Loenhout-Rooyakkers J, et al. Direct and indirect costs of tuberculosis among immigrant patients in the Netherlands. BMC PublicHealth.2009; 9(1): 283.
  21. Jackson S, Sleigh AC, Wang GJ, Liu XL.Poverty and the economic effects of TB in rural China.Int J Tuberc Lung Dis. 2006;10(10): 1104-1110.
  22. Wyss K, Kilima P, Lorenz N. Costs of tuberculosis for households and health care providers in Dar es Salaam, Tanzania.TropicalMedicine and International Health.2001; 6(1): 60-68.
  23. Schwarzmann K, Oxlade O, Barr RG, et al. Domestic returns from investment in the control of tuberculosis in other countries. N Engl J Med 2005; 353: 1008-1020.
  24. Elamin EI, Ibrahim MI, Sulaiman SA, Muttalif AR. Cost of illness of tuberculosis in Penang, Malaysia. Pharm World Sci.2008; 30(3): 281-286.